Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to asse

Guggenheim analyst Subbu Nambi maintains Natera (NASDAQ:NTRA) with a Buy and raises the price tar

Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they ​have partne

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomi

AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cel

Bernstein analyst Eve Burstein reiterates Natera (NASDAQ:NTRA) with a Outperform and announces $310

Bernstein analyst Eve Burstein reiterates Natera (NASDAQ:NTRA) with a Outperform and announces $3

Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test

Natera (NTRA) saw its shares surge in the last session with trading volume being higher than average

Eledon has established the regulatory framework for its Phase 3 kidney transplantation program and p

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cel

Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Barclays analyst Luke Sergott maintains Natera (NASDAQ:NTRA) with a Overweight and lowers the pri

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target f

Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

RBC Capital analyst Dan Leonard reinstates Natera (NASDAQ:NTRA) with a Outperform and announces $

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets

Goldman Sachs analyst Evie Koslosky initiates coverage on Natera (NASDAQ:NTRA) with a Neutral rat

Under the agreement, Natera will assess CytoDyn clinical trial samples from the CLOVER Phase 2 study

Wolfe Research analyst Mike Polark assumes Natera (NASDAQ:NTRA) with a Outperform rating and anno

The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combin

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine,

Company to open second facility and new lab space to accommodate rapid growthNatera, Inc. (NASDAQ:NT

EXPAND is a prospective, blinded, multi-site clinical trial designed to study Natera's Fetal Foc

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and lowers the price target f

JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and raises the

Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and

Wells Fargo analyst Brandon Couillard maintains Natera (NASDAQ:NTRA) with a Equal-Weight and rais

Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.620 billion-$2.700 billion to $2.740 billio

Natera (NASDAQ:NTRA) reported quarterly losses of $(0.60) per share which missed the analyst consens

https://www.wsj.com/tech/ai/ai-investor-coatue-joins-data-center-frenzy-with-new-venture-to-buy-land

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d

Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with Arche

Discover last week's top 10 large-cap stock gainers, why they rallied, and what catalysts drove

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for a

Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23

Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance,